Since first publication of its study results in The New England Journal of Medicine in October 2003, a technology detecting an enzyme from “culprit lesions” of the heart – developed at the Cleveland Clinic (Cleveland) to determine patients who are in imminent danger of heart attack or death – has been approved by the FDA.